<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00690872</url>
  </required_header>
  <id_info>
    <org_study_id>CDR0000577971</org_study_id>
    <secondary_id>SINGAPORE-07-27-NPC</secondary_id>
    <nct_id>NCT00690872</nct_id>
  </id_info>
  <brief_title>Gemcitabine and Carboplatin Followed By Laboratory-Treated T Lymphocytes in Treating Patients With Metastatic or Locally Recurrent Epstein-Barr Virus-Positive Nasopharyngeal Cancer</brief_title>
  <official_title>Phase II Trial Evaluating Efficacy of a Strategy Employing Combination Gemcitabine and Carboplatin Chemotherapy Followed by EBV-Specific Cytotoxic T-Lymphocytes in Patients With Metastatic or Locally Recurrent EBV-Positive Nasopharyngeal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>National Cancer Centre, Singapore</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>National Cancer Institute (NCI)</source>
  <brief_summary>
    <textblock>
      RATIONALE: Drugs used in chemotherapy, such as gemcitabine and carboplatin, work in different&#xD;
      ways to stop the growth of tumor cells, either by killing the cells or by stopping them from&#xD;
      dividing. Giving an infusion of a person's T lymphocytes that have been treated in the&#xD;
      laboratory may help the body build an effective immune response to kill tumor cells. Giving&#xD;
      combination chemotherapy together with laboratory-treated T lymphocytes may kill more tumor&#xD;
      cells.&#xD;
&#xD;
      PURPOSE: This phase II trial is studying how well giving gemcitabine and carboplatin together&#xD;
      with laboratory-treated T lymphocytes works in treating patients with metastatic or locally&#xD;
      recurrent Epstein-Barr virus-positive nasopharyngeal cancer.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      OBJECTIVES:&#xD;
&#xD;
      Primary&#xD;
&#xD;
        -  To determine progression-free survival (PFS 1) of patients with metastatic or locally&#xD;
           recurrent Epstein-Barr virus (EBV)-positive nasopharyngeal carcinoma treated with&#xD;
           gemcitabine hydrochloride and carboplatin followed EBV-specific cytotoxic T-lymphocytes&#xD;
           (CTL).&#xD;
&#xD;
      Secondary&#xD;
&#xD;
        -  To determine progression-free survival (PFS 2) of these patients during the&#xD;
           immunotherapy portion of this study.&#xD;
&#xD;
        -  To determine the clinical benefit rate of EBV-specific CTL in these patients.&#xD;
&#xD;
        -  To determine the tolerability of EBV-specific CTL therapy in these patients.&#xD;
&#xD;
        -  To demonstrate persistence of EBV-specific immune response in these patients.&#xD;
&#xD;
      OUTLINE: Patients undergo collection of peripheral blood mononuclear cells (PBMC) from which&#xD;
      T cells are purified, co-cultured with irradiated autologous Epstein-Barr virus&#xD;
      (EBV)-specific cytotoxic T-lymphocytes (CTLs), and expanded in vitro for the establishment of&#xD;
      cytotoxic T-cell lines.&#xD;
&#xD;
        -  Chemotherapy: Patients receive gemcitabine hydrochloride IV over 30 minutes and&#xD;
           carboplatin IV over 60 minutes on days 1, 8, and 15. Treatment repeats every 28 days for&#xD;
           up to 4 courses in the absence of disease progression or unacceptable toxicity. After&#xD;
           completion of course 2, patients undergo evaluation for response. Patients with&#xD;
           progressive disease proceed directly to induction immunotherapy. Patients with stable&#xD;
           disease (SD), partial response (PR), or complete response (CR) receive 2 additional&#xD;
           courses of chemotherapy and then proceed to induction immunotherapy.&#xD;
&#xD;
        -  Induction immunotherapy: Beginning 14-28 days after the completion of chemotherapy,&#xD;
           patients receive EBV-specific CTLs IV over 1-10 minutes on days 1 and 14. Six weeks&#xD;
           after the second infusion, patients undergo evaluation for response. Patients who&#xD;
           demonstrate clinical benefit (i.e., CR, PR, SD) to induction immunotherapy proceed to&#xD;
           maintenance immunotherapy.&#xD;
&#xD;
        -  Maintenance immunotherapy: Patients receive EBV-specific CTLs IV over 1-10 minutes.&#xD;
           Treatment repeats every 1-3 months for up to 4 courses in the absence of disease&#xD;
           progression or unacceptable toxicity.&#xD;
&#xD;
      Patients undergo blood sample collection at baseline and prior to each course of induction&#xD;
      immunotherapy and maintenance immunotherapy. Samples are analyzed for EBV CTL frequency by&#xD;
      immune function assays (i.e., tetramer analysis, enzyme-linked immunospot, and cytotoxic&#xD;
      T-lymphocyte precursor assays); for specificity of response by cytotoxicity assays (in&#xD;
      patients for whom the appropriate reagents are available); and for evaluation of EBV DNA by&#xD;
      polymerase chain reaction. In addition, T-cells are isolated from blood samples for&#xD;
      fluorescence-activated cell sorter analysis and for extraction of RNA.&#xD;
&#xD;
      After completion of study therapy, patients are followed at least every 2 months until&#xD;
      disease progression.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>July 2008</start_date>
  <primary_completion_date type="Anticipated">December 2014</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Median progression-free survival (PFS 1), defined as the time from study enrollment to the time of radiological disease progression or death from any cause</measure>
  </primary_outcome>
  <secondary_outcome>
    <measure>Median PFS 2, defined as the time from the start of induction immunotherapy to radiological disease progression or death from any cause</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Response rate, defined as the proportion of patients who achieve a complete response (CR) or partial response (PR) after 4 courses of chemotherapy and the proportion of patients who achieve a further response after immunotherapy</measure>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Clinical benefit rate of immunotherapy, defined as the proportion of patients who achieve CR, PR, or stable disease</measure>
  </secondary_outcome>
  <enrollment type="Anticipated">35</enrollment>
  <condition>Head and Neck Cancer</condition>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>autologous Epstein-Barr virus-specific cytotoxic T lymphocytes</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>carboplatin</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>gemcitabine hydrochloride</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>polymerase chain reaction</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>fluorescence activated cell sorting</intervention_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>immunoenzyme technique</intervention_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        DISEASE CHARACTERISTICS:&#xD;
&#xD;
          -  Biopsy-proven nasopharyngeal carcinoma (NPC)&#xD;
&#xD;
               -  WHO type 2/3 disease&#xD;
&#xD;
               -  Metastatic or locally recurrent disease&#xD;
&#xD;
          -  Epstein-Barr virus (EBV)-positive disease as confirmed by in situ hybridization assay&#xD;
             or PCR amplification for EBV-encoded RNA expression&#xD;
&#xD;
          -  Radiologically measurable disease&#xD;
&#xD;
        PATIENT CHARACTERISTICS:&#xD;
&#xD;
          -  ECOG performance status 0-2&#xD;
&#xD;
          -  Life expectancy &gt; 3 months&#xD;
&#xD;
          -  ANC &gt; 1,200/mm^3&#xD;
&#xD;
          -  Platelet count ≥ 100,000/mm^3&#xD;
&#xD;
          -  Hemoglobin ≥ 8 g/dL&#xD;
&#xD;
          -  Bilirubin &lt; 2 times upper limit of normal (ULN)&#xD;
&#xD;
          -  AST and ALT &lt; 3 times ULN&#xD;
&#xD;
          -  Creatinine clearance ≥ 40 mL/min&#xD;
&#xD;
          -  Corrected calcium normal&#xD;
&#xD;
          -  Not pregnant or nursing&#xD;
&#xD;
          -  Negative pregnancy test&#xD;
&#xD;
          -  Fertile patients must use effective contraception&#xD;
&#xD;
          -  No concurrent severe illness, including any of the following:&#xD;
&#xD;
               -  Chronic obstructive pulmonary disease&#xD;
&#xD;
               -  Ischemic heart disease&#xD;
&#xD;
               -  Active congestive cardiac failure&#xD;
&#xD;
               -  Active angina pectoris&#xD;
&#xD;
               -  Uncontrolled arrhythmia&#xD;
&#xD;
               -  Uncontrolled hypertension&#xD;
&#xD;
          -  No concurrent severe infections&#xD;
&#xD;
          -  HIV negative&#xD;
&#xD;
        PRIOR CONCURRENT THERAPY:&#xD;
&#xD;
          -  No more than one line of prior chemotherapy for metastatic disease&#xD;
&#xD;
          -  No prior gemcitabine hydrochloride&#xD;
&#xD;
          -  Prior platinum agents allowed&#xD;
&#xD;
          -  At least 1 month since prior investigational therapy&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Toh Han Chong, MD, MBBS, MRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>National Cancer Centre, Singapore</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>National Cancer Centre - Singapore</name>
      <address>
        <city>Singapore</city>
        <zip>169610</zip>
        <country>Singapore</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Toh Han Chong, MD, MBBS, MRCP</last_name>
      <phone>65-6436-8172</phone>
    </contact>
  </location>
  <location_countries>
    <country>Singapore</country>
  </location_countries>
  <verification_date>June 2009</verification_date>
  <study_first_submitted>June 4, 2008</study_first_submitted>
  <study_first_submitted_qc>June 4, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">June 5, 2008</study_first_posted>
  <last_update_submitted>June 26, 2009</last_update_submitted>
  <last_update_submitted_qc>June 26, 2009</last_update_submitted_qc>
  <last_update_posted type="Estimate">June 29, 2009</last_update_posted>
  <keyword>recurrent lymphoepithelioma of the nasopharynx</keyword>
  <keyword>recurrent squamous cell carcinoma of the nasopharynx</keyword>
  <keyword>stage IV lymphoepithelioma of the nasopharynx</keyword>
  <keyword>stage IV squamous cell carcinoma of the nasopharynx</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Head and Neck Neoplasms</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Gemcitabine</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

